Acrivon draws in $130M; Vincerx Pharma's Ph1 metastatic tumor data
09 Apr 2024
Acrivon raises $130M PIPE: The precision oncology biotech brought in the money from RA Capital, Perceptive Advisors and other investors. Its stock $ACRV was up more than 50% in early Tuesday trading. — Kyle LaHucik
Vincerx Pharma’s Ph1 metastatic tumor data disappoints investors: The company’s VIP236 was well-tolerated with no dose-limiting toxicities when given once every three weeks, according to results presented at the American Association for Cancer ResearchCancer Research’s annual meeting. Of the 15 patients treated, seven achieved objective stable disease, but there were no RECIST responses. The company’s stock $VINC was down about 75% on Tuesday morning. — Ayisha Sharma
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.